Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P. Erba, Richard F. Schlenk, Yasser Mostafa Kamel et al.|The Lancet|2023Cited by 387
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W. Wijermans, Michal Kiciński et al.|The Lancet Haematology|2023Cited by 39
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trialFabio Efficace, Michael Lübbert, Michal Kiciński et al.|Blood|2024Cited by 18
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study groupMichael Lübbert, Gerwin Huls, Pierre W. Wijermans et al.|Blood|2025Cited by 1
Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study groupJulia Stomper, Michael Lübbert, Michal Kiciński et al.|Blood|2025Cited by 0